Pfizer hires McKinsey's Aamir Malik as dealmaking chief
Pharmaceutical giant Pfizer has hired Aamir Malik, a senior partner in McKinsey & Company’s pharma & medical products practice, as EVP and chief business innovation officer.
In the role, Malik will oversee Pfizer’s strategy, business development, portfolio management, pipeline prioritization, formation of new ventures, and access partnerships with payers and governments. He joins the company effective August 30 and will report to CEO Albert Bourla.
Malik succeeds John Young, who held the role for the last three years. Young will retire in 2022, having spent 34 years at Pfizer. As dealmaking leader, Young oversaw the company’s Covid-19 vaccine collaboration with BioNTech.
Pfizer’s Covid-19 vaccine is expected to have 2021 sales of $33.5 billion, giving Malik a healthy amount of cash to drive future transactions.
“We are delighted to welcome Aamir Malik to our executive leadership team in this important role as we enter the next era of innovation for Pfizer and continue our pursuit of both cutting-edge science and opportunities to reimagine how we do business for the benefit of patients and society,” Bourla said.
Malik has 25 years of experience developing growth strategies, guiding M&A, and implementing large-scale programs at life sciences firms. He has worked at management consultancy McKinsey & Company since 1997, and is based in the firm’s Summit, New Jersey office – a global hub for its work in healthcare and biopharma.
Malik most recently served as managing partner of McKinsey’s US operations, and before that led the firm’s global pharmaceuticals & medical products practice. His work has included advising on several of the largest healthcare M&A deals of the past two decades.
He holds a bachelor’s degree in finance from Indiana University Bloomington.
